New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.

CONCLUSIONS: Antiangiogenic agents can achieve therapeutic benefit in advanced NSCLC patients and the combination of chemotherapy, targeted therapy or immunotherapy can lead to synergistic effect. However, exploring the best combination therapy and efficacy-related biomarkers needs further study.
PMID: 32065262 [PubMed - as supplied by publisher]

Source: Clin Med Res - February 16, 2020 Category: Research Authors: Qiang H, Chang Q, Xu J, Qian J, Zhang Y, Lei Y, Han B, Chu T Tags: J Cancer Res Clin Oncol Source Type: research